Cargando…

Role of Intravitreal Bevacizumab in Management of Eale’s Disease

OBJECTIVE: To investigate the role of Intravitreal Bevacizumab (IVB), in preventing vitreo-retinal complications in patients of Eale’s Disease (ED). METHODS: This randomized control trial was conducted at Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi from May 2015 to December 2016. A to...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehboob, Mohammad Asim, Tahir, Muhammad, Batool, Huma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954374/
https://www.ncbi.nlm.nih.gov/pubmed/29805403
http://dx.doi.org/10.12669/pjms.342.14483
_version_ 1783323508323909632
author Mehboob, Mohammad Asim
Tahir, Muhammad
Batool, Huma
author_facet Mehboob, Mohammad Asim
Tahir, Muhammad
Batool, Huma
author_sort Mehboob, Mohammad Asim
collection PubMed
description OBJECTIVE: To investigate the role of Intravitreal Bevacizumab (IVB), in preventing vitreo-retinal complications in patients of Eale’s Disease (ED). METHODS: This randomized control trial was conducted at Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi from May 2015 to December 2016. A total of 52 eyes of 26 patients, diagnosed with stage I or II of ED were randomly divided in two groups. Group A received monthly injections of IVB for 3 months, with steroids and laser photocoagulation. Group B received only steroids and laser treatment. Patients were followed for three months, and were analyzed for different clinical parameters. RESULTS: Mean age of study population was 28.5±2.64 years. Difference in frequency of patients requiring PPV and showing regression in neovascularization was statistically significant between both groups (p=0.005 for both). However, difference in frequency of patients showing progression in stage of ED, regression of vasculitis and best corrected visual acuity at 12 weeks between two groups was not statistically significant (p= 0.012, 0.579, 0.046 respectively). CONCLUSION: Intravitreal Bevacizumab injection, given monthly in patients of ED results in significantly more regression in neovascularization, and less requirement for PPV, as compared to those receiving standard steroids and laser photocoagulation treatment.
format Online
Article
Text
id pubmed-5954374
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Professional Medical Publications
record_format MEDLINE/PubMed
spelling pubmed-59543742018-05-25 Role of Intravitreal Bevacizumab in Management of Eale’s Disease Mehboob, Mohammad Asim Tahir, Muhammad Batool, Huma Pak J Med Sci Original Article OBJECTIVE: To investigate the role of Intravitreal Bevacizumab (IVB), in preventing vitreo-retinal complications in patients of Eale’s Disease (ED). METHODS: This randomized control trial was conducted at Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi from May 2015 to December 2016. A total of 52 eyes of 26 patients, diagnosed with stage I or II of ED were randomly divided in two groups. Group A received monthly injections of IVB for 3 months, with steroids and laser photocoagulation. Group B received only steroids and laser treatment. Patients were followed for three months, and were analyzed for different clinical parameters. RESULTS: Mean age of study population was 28.5±2.64 years. Difference in frequency of patients requiring PPV and showing regression in neovascularization was statistically significant between both groups (p=0.005 for both). However, difference in frequency of patients showing progression in stage of ED, regression of vasculitis and best corrected visual acuity at 12 weeks between two groups was not statistically significant (p= 0.012, 0.579, 0.046 respectively). CONCLUSION: Intravitreal Bevacizumab injection, given monthly in patients of ED results in significantly more regression in neovascularization, and less requirement for PPV, as compared to those receiving standard steroids and laser photocoagulation treatment. Professional Medical Publications 2018 /pmc/articles/PMC5954374/ /pubmed/29805403 http://dx.doi.org/10.12669/pjms.342.14483 Text en Copyright: © Pakistan Journal of Medical Sciences http://creativecommons.org/licenses/by/3.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Mehboob, Mohammad Asim
Tahir, Muhammad
Batool, Huma
Role of Intravitreal Bevacizumab in Management of Eale’s Disease
title Role of Intravitreal Bevacizumab in Management of Eale’s Disease
title_full Role of Intravitreal Bevacizumab in Management of Eale’s Disease
title_fullStr Role of Intravitreal Bevacizumab in Management of Eale’s Disease
title_full_unstemmed Role of Intravitreal Bevacizumab in Management of Eale’s Disease
title_short Role of Intravitreal Bevacizumab in Management of Eale’s Disease
title_sort role of intravitreal bevacizumab in management of eale’s disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5954374/
https://www.ncbi.nlm.nih.gov/pubmed/29805403
http://dx.doi.org/10.12669/pjms.342.14483
work_keys_str_mv AT mehboobmohammadasim roleofintravitrealbevacizumabinmanagementofealesdisease
AT tahirmuhammad roleofintravitrealbevacizumabinmanagementofealesdisease
AT batoolhuma roleofintravitrealbevacizumabinmanagementofealesdisease